Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer is a research paper published in Journal of Clinical Oncology (2023). On theSindex it has a DataRank of 4.4. It has been cited 181 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.781
From this paper's citation signal
Citation Network Contribution
3.6
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NCATS NIH HHS
Grant: UL1 TR001863
NCI NIH HHS
Grant: K12 CA076917
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 2K12CA076917-21
Clinical Oncology Research Program (CORP)
FWCI
46.79
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals